"Breakthrough" Tells The story Of Dr. Jim Allison, A Nobel Prize-Winner For Immunotherapy
- “Breakthrough,” is a film about the life of Dr. Jim Allison and his Nobel Prize-winning work in immunotherapy and its profound impact on reducing cancer mortality.
- Dr. Allison’s personal drive to fight cancer, fueled by his family’s own struggles with the disease, inspired his groundbreaking immunological research.
- His perseverance led to the development of checkpoint inhibitors, revolutionizing the treatment of late-stage lung cancer.
- Reviewing in depth information about immunotherapy can help you understand if this is the right treatment for you.
He is Chair of the Department of Immunology at MD Anderson Cancer Center in Houston, TX, and his groundbreaking work in immunotherapy has reduced cancer-related mortality.
Read More
All in the family
Dr. Allison was born in 1948 in Alice, Texas.Dr. Allison lost his mom to lymphoma when he was just 11 years old. His mom’s brother passed away from melanoma and her other brother had lung cancer.
Dr. Allison remembers his mother’s lymphoma treatment, saying, “All I knew was she was sick, and she had these burns on her throat, and she was in bed a lot. She was dying, Allison recalls.
With so much cancer in his family, Dr. Allison was inspired to seek answers.
A big discovery
Dr. Allison discovered T cells in college, which sparked his interest in them.
T cells are white blood cells that respond to viral and bacterial infections. He later worked at the MD Anderson Cancer Center in Texas, where he made major breakthroughs in understanding T cells and the T cell receptor.
Dr. Allison used pioneering engineering techniques to test his hypothesis about T cells and their ability to fight cancer. Immunotherapy initially faced skepticism, but Dr. Allison persevered, as he always did.
For years, clinical trials for immunotherapy didn’t work. So there was a belief among some in the oncology community that the therapy would never work.
Dr. Allison smartly targeted biotech companies that might be willing to gamble on his immunotherapy ideas, which centered on the body using its own immune system to recognize and fight cancer.
Ultimately, Dr. Allison and his team made progress on the immunotherapy science, and the data proved it effective. Dr. Allison’s work has now saved the lives of hundreds of thousands of people diagnosed with cancer.
Immunotherapy for late-stage lung cancer
If you’ve been diagnosed with late-stage lung cancer, keep reading to learn more about immunotherapy and how it can help you live a longer, healthier life. Here are the highlights:
- Immunotherapy works by boosting the immune system response against lung cancer.
- Today, immunotherapy is a first treatment for many people with late-stage lung cancer unless you have a specific mutation that is likely to reduce its effectiveness.
- Researchers are studying new targets for lung cancer immunotherapy in clinical trials.
- Even if you receive immunotherapy, you may still undergo more traditional treatments like chemotherapy and radiation as well.
Advanced-stage cancer is generally not considered curable. However, immunotherapy is making it more treatable.
What are checkpoint inhibitors?
When doctors recommend immunotherapy for lung cancer, they are usually referring to checkpoint inhibitors.
Here is how they work:
- Checkpoints are proteins on T cells, which is a type of immune cell. T cells attack harmful substances such as bacteria, viruses, and even cancer cells. PD-1 is an example of a checkpoint found on this type of immune cell.
- Lung cancer cells carry their own protein, known as PD-L1. Think of it as a cloak that helps it hide from the immune system.
- The PD-1 to PD-L1 interaction turns the immune system ‘off’, allowing cancer cells to hide. When the interaction is blocked by either PD-1 or PD-L1 inhibitors, suddenly the negative switch is turned off, and the immune system can begin destroying and ultimately killing cancer cells.
- One group of checkpoint inhibitors blocks PD-1. This essentially flips the switch ‘on’ for T cells to unleash them on the cancer.
However, like other cancer treatments, these drugs aren’t universally effective, and about 10% of patients have serious side effects, including:
- Fatigue
- Rashes
- Diarrhea
- Weakness
- Headache
- Impaired thyroid function
The biggest worry is that by unleashing the body’s immune system, this treatment might trigger damaging inflammation. Essentially, your body could start to attack its own organs, which would be troublesome, to say the least. If this happens, the side effects are often irreversible and you may have them for life.
Related: How Genetic Testing Determines Treatment in Lung Cancer
Biomarker testing
To see whether you are a good candidate for checkpoint inhibitors, your doctor will likely order a biomarker test.
Biomarker testing is the key to unlocking personalized treatment in late-stage lung cancer. This is what it involves:
- You will have a biopsy to remove a small sample of tumor tissue to help identify specific cancer characteristics.
- Tests usually check for PDL-1. Its presence can indicate how effective certain immunotherapies may be for you. High levels of PD-L1 biomarkers suggest you may benefit from immunotherapy. Specific genetic mutations can signal that certain treatments may be less effective.
- Results help doctors tailor treatment to a tumor’s unique biomarkers so they can deliver a potentially more effective way to combat late-stage lung cancer.
While biomarker testing in lung cancer assesses specific proteins and molecules to guide treatment choices, genetic testing looks for inherited or acquired genetic mutations within the cancer cells.
Any patient diagnosed with late-stage lung cancer should also consider genetic testing, as it can reveal targeted treatment options.
In the pipeline
Several new immunotherapies are moving through clinical trials. This is a major step toward expanding treatment options.
Some studies are looking at various different checkpoint targets. The more checkpoints doctors can target, the better the responses.
Cancer vaccines are another investigational immunotherapy. Just as a vaccine for the flu or COVID-19 generates an immune response against a virus, these vaccines would trigger an immune response against cancer. This may be the future of cancer treatment and prevention.
Learn more about SurvivorNet's rigorous medical review process.
